Li Zheng, Shi Jiajie, Wu Xiaolin, Yan Siyao, Gao Zhe, Liu Yueping
Department of Hematology, Hebei Medical University Fourth Hospital Shijiazhuang 050000, Hebei, China.
Department of Breast Surgery, Hebei Medical University Fourth Hospital Shijiazhuang 050000, Hebei, China.
Am J Cancer Res. 2025 May 25;15(5):2285-2300. doi: 10.62347/DIMG6893. eCollection 2025.
To investigate the relationship between the gut microbiota and the biological characteristics of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
This prospective study included 71 patients with newly diagnosed DLBCL. The microbiota was analyzed using 16S ribosomal DNA sequencing of fecal samples. Blood cytokines, PD-1, and PD-L1 were measured by enzyme-linked immunosorbent assay. Stratified analyses based on clinical characteristics were conducted to investigate correlations between alterations in gut microbiota and key clinicopathological parameters of DLBCL.
In the analysis of gut microbiota heterogeneity (α diversity index), species abundance was significantly higher in the International Prognostic Index (IPI) < 3 group compared to the IPI ≥ 3 group (high-risk group). Ruminococcus was increased in the IPI ≥ 3 group. Parabacteroides, Ruminococcus, and Eubacterium were increased in the non-germinal center B-cell-like group, while Lachnospira was decreased. Megamonas was significantly increased in the high β2-microglobulin group, while Lactobacillus reuteri and Lachnospira were decreased. In the low CD4+/CD8+ ratio group, Parabacteroides was increased, while Akkermansia was decreased. Patients who failed to achieve complete remission at interim evaluation showed marked increases in Ruminococcus and Alistipes. Extranodal involvement was associated with elevated Alistipes and Enterococcus.
This study identified a potential relationship between the gut microbiota and DLBCL characteristics, highlighting specific gut microbiota organisms that may influence disease development and progression.
探讨肠道微生物群与新诊断的弥漫性大B细胞淋巴瘤（DLBCL）患者生物学特征之间的关系。
这项前瞻性研究纳入了71例新诊断的DLBCL患者。使用粪便样本的16S核糖体DNA测序分析微生物群。通过酶联免疫吸附测定法检测血中细胞因子、PD-1和PD-L1。基于临床特征进行分层分析，以研究肠道微生物群改变与DLBCL关键临床病理参数之间的相关性。
在肠道微生物群异质性（α多样性指数）分析中，国际预后指数（IPI）<3组的物种丰度显著高于IPI≥3组（高危组）。IPI≥3组中瘤胃球菌增加。在非生发中心B细胞样组中，副拟杆菌、瘤胃球菌和真杆菌增加，而毛螺菌减少。在高β2微球蛋白组中，巨单胞菌显著增加，而罗伊氏乳杆菌和毛螺菌减少。在低CD4+/CD8+比值组中，副拟杆菌增加，而阿克曼氏菌减少。在中期评估时未达到完全缓解的患者中，瘤胃球菌和艾氏菌显著增加。结外受累与艾氏菌和肠球菌升高有关。
本研究确定了肠道微生物群与DLBCL特征之间的潜在关系，突出了可能影响疾病发生和进展的特定肠道微生物群。
